Nona Biosciences Enters into Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
Thursday, November 06, 2025
Nona Biosciences has announced an expanded evaluation and licence agreement with Umoja Biopharma.
The new agreement builds upon the strategic partnership established between the two companies in September 2024. The collaboration aims to develop multiple in vivo CAR-T cell products by combining Nona’s proprietary HCAb Harbour Mice® and NonaCarFx™ platforms with Umoja’s VivoVec™ technology.
As part of the agreement, Nona Biosciences will receive an upfront payment along with potential option exercise fees and milestone payments linked to the progress of specific discovery and development programmes. Umoja Biopharma will lead further product development and commercialisation efforts.
The collaboration strengthens the ongoing relationship between the two organisations, combining Nona’s advanced antibody discovery and immunology expertise with Umoja’s innovative cell therapy technology.
The partnership is expected to accelerate the creation of next-generation in vivo CAR-T cell therapies aimed at improving treatment accessibility and patient outcomes.
Source: prnewswire.com
